Cingulate (CING) Stock Price, News & Analysis

Company Overview

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key Stats

• Today's Range: $4.01 to $4.38
• 50-Day Range: $3.98 to $5.73
• 52-Week Range: $1.80 to $20.83
• Volume: 162,051 shs
• Average Volume: 140,627 shs
• Market Capitalization: $21.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Buy

Cingulate Stock Analysis - MarketRank™

Cingulate scored higher than 46% of companies evaluated by MarketBeat, and ranked 596th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cingulate has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cingulate has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cingulate are expected to grow in the coming year, from ($11.69) to ($4.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cingulate is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cingulate is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cingulate has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.28% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cingulate has recently decreased by 16.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cingulate does not currently pay a dividend.

Dividend Growth

Cingulate does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.28% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cingulate has recently decreased by 16.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 6 news articles for Cingulate this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Cingulate to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cingulate insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.27% of the stock of Cingulate is held by insiders.

Percentage Held by Institutions

41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CING Stock Analysis - Frequently Asked Questions

How have CING shares performed this year?

Cingulate's stock was trading at $4.93 at the beginning of 2025. Since then, CING stock has decreased by 15.4% and is now trading at $4.17.

How were Cingulate's earnings last quarter?

Cingulate Inc. (NASDAQ:CING) issued its earnings results on Thursday, May, 8th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.00) by $0.04.

When did Cingulate's stock split?

Cingulate shares reverse split on the morning of Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cingulate own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Altamira Therapeutics (CYTO).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CING
• CIK: 1862150
• Web: www.cingulate.com
• Phone: 913-942-2300
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cingulate: $26.00
• High Price Target: $61.00
• Low Price Target: $11.00
• Potential Upside/Downside: +523.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -229.78%
• Return on Assets: -142.28%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 1.87
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.32 per share
• Price / Book: 1.80

Miscellaneous

• Outstanding Shares: 5,260,000
• Free Float: 4,988,000
• Market Cap: $21.93 million
• Optionable: Not Optionable
• Beta: -0.74